tetano
Editor, Senior Moderator
JAMA Netw Open
. 2024 Jun 3;7(6):e2417977.
doi: 10.1001/jamanetworkopen.2024.17977. Cannabis, Tobacco Use, and COVID-19 Outcomes
Nicholas B Griffith[SUP] 1 [/SUP], Timothy B Baker[SUP] 2 [/SUP], Brendan T Heiden[SUP] 3 4 [/SUP], Nina Smock[SUP] 5 [/SUP], Giang Pham[SUP] 5 [/SUP], Jingling Chen[SUP] 5 [/SUP], Justin Yu[SUP] 1 [/SUP], James Reddy[SUP] 5 [/SUP], Albert M Lai[SUP] 1 [/SUP], Eric Hogue[SUP] 1 [/SUP], Laura J Bierut[SUP] 5 [/SUP], Li-Shiun Chen[SUP] 5 6 [/SUP]
Affiliations
Importance: It is unclear whether cannabis use is associated with adverse health outcomes in patients with COVID-19 when accounting for known risk factors, including tobacco use.
Objective: To examine whether cannabis and tobacco use are associated with adverse health outcomes from COVID-19 in the context of other known risk factors.
Design, setting, and participants: This retrospective cohort study used electronic health record data from February 1, 2020, to January 31, 2022. This study included patients who were identified as having COVID-19 during at least 1 medical visit at a large academic medical center in the Midwest US.
Exposures: Current cannabis use and tobacco smoking, as documented in the medical encounter.
Main outcomes and measures: Health outcomes of hospitalization, intensive care unit (ICU) admission, and all-cause mortality following COVID-19 infection. The association between substance use (cannabis and tobacco) and these COVID-19 outcomes was assessed using multivariable modeling.
Results: A total of 72 501 patients with COVID-19 were included (mean [SD] age, 48.9 [19.3] years; 43 315 [59.7%] female; 9710 [13.4%] had current smoking; 17 654 [24.4%] had former smoking; and 7060 [9.7%] had current use of cannabis). Current tobacco smoking was significantly associated with increased risk of hospitalization (odds ratio [OR], 1.72; 95% CI, 1.62-1.82; P < .001), ICU admission (OR, 1.22; 95% CI, 1.10-1.34; P < .001), and all-cause mortality (OR, 1.37, 95% CI, 1.20-1.57; P < .001) after adjusting for other factors. Cannabis use was significantly associated with increased risk of hospitalization (OR, 1.80; 95% CI, 1.68-1.93; P < .001) and ICU admission (OR, 1.27; 95% CI, 1.14-1.41; P < .001) but not with all-cause mortality (OR, 0.97; 95% CI, 0.82-1.14, P = .69) after adjusting for tobacco smoking, vaccination, comorbidity, diagnosis date, and demographic factors.
Conclusions and relevance: The findings of this cohort study suggest that cannabis use may be an independent risk factor for COVID-19-related complications, even after considering cigarette smoking, vaccination status, comorbidities, and other risk factors.
. 2024 Jun 3;7(6):e2417977.
doi: 10.1001/jamanetworkopen.2024.17977. Cannabis, Tobacco Use, and COVID-19 Outcomes
Nicholas B Griffith[SUP] 1 [/SUP], Timothy B Baker[SUP] 2 [/SUP], Brendan T Heiden[SUP] 3 4 [/SUP], Nina Smock[SUP] 5 [/SUP], Giang Pham[SUP] 5 [/SUP], Jingling Chen[SUP] 5 [/SUP], Justin Yu[SUP] 1 [/SUP], James Reddy[SUP] 5 [/SUP], Albert M Lai[SUP] 1 [/SUP], Eric Hogue[SUP] 1 [/SUP], Laura J Bierut[SUP] 5 [/SUP], Li-Shiun Chen[SUP] 5 6 [/SUP]
Affiliations
- PMID: 38904961
- PMCID: PMC11193123
- DOI: 10.1001/jamanetworkopen.2024.17977
Importance: It is unclear whether cannabis use is associated with adverse health outcomes in patients with COVID-19 when accounting for known risk factors, including tobacco use.
Objective: To examine whether cannabis and tobacco use are associated with adverse health outcomes from COVID-19 in the context of other known risk factors.
Design, setting, and participants: This retrospective cohort study used electronic health record data from February 1, 2020, to January 31, 2022. This study included patients who were identified as having COVID-19 during at least 1 medical visit at a large academic medical center in the Midwest US.
Exposures: Current cannabis use and tobacco smoking, as documented in the medical encounter.
Main outcomes and measures: Health outcomes of hospitalization, intensive care unit (ICU) admission, and all-cause mortality following COVID-19 infection. The association between substance use (cannabis and tobacco) and these COVID-19 outcomes was assessed using multivariable modeling.
Results: A total of 72 501 patients with COVID-19 were included (mean [SD] age, 48.9 [19.3] years; 43 315 [59.7%] female; 9710 [13.4%] had current smoking; 17 654 [24.4%] had former smoking; and 7060 [9.7%] had current use of cannabis). Current tobacco smoking was significantly associated with increased risk of hospitalization (odds ratio [OR], 1.72; 95% CI, 1.62-1.82; P < .001), ICU admission (OR, 1.22; 95% CI, 1.10-1.34; P < .001), and all-cause mortality (OR, 1.37, 95% CI, 1.20-1.57; P < .001) after adjusting for other factors. Cannabis use was significantly associated with increased risk of hospitalization (OR, 1.80; 95% CI, 1.68-1.93; P < .001) and ICU admission (OR, 1.27; 95% CI, 1.14-1.41; P < .001) but not with all-cause mortality (OR, 0.97; 95% CI, 0.82-1.14, P = .69) after adjusting for tobacco smoking, vaccination, comorbidity, diagnosis date, and demographic factors.
Conclusions and relevance: The findings of this cohort study suggest that cannabis use may be an independent risk factor for COVID-19-related complications, even after considering cigarette smoking, vaccination status, comorbidities, and other risk factors.